Marvel Announces an Extension to Its Collaboration With The IBraiN Institute to Test MB204 In a Pre-Clinical Model of Rett Syndrome
Marvel Announces an Extension to Its Collaboration With The IBraiN Institute to Test MB204 In a Pre-Clinical Model of Rett Syndrome
Calgary, Alberta--(Newsfile Corp. - July 24, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce the extension of its collaboration with Drs. Julie Le Merrer and Jerome Becker, lead investigators at the iBraiN Institute in Tours France. Building upon the promising results using MB204 in an autism model earlier this year, we now aim to test our lead asset in a mouse model of Rett syndrome (Mecp2).
Newsfile公司--加拿大阿爾伯塔省卡爾加里市,2024年7月24日---Marvel Biosciences公司 (TSXV: MRVL) (OTCQB: MBCOF)及其全資子公司Marvel生物技術公司(統稱"公司"或"Marvel")今天高興地宣佈延長與法國圖爾市iBraiN研究所主要研究員Julie Le Merrer博士和Jerome Becker博士的合作。基於今年早些時候在自閉症模型中使用MB204得到的有希望的結果,我們現在打算在Rett綜合徵(Mecp2)的鼠模型中測試我們的主打資產。
Rett syndrome and autism share several genetic, clinical and neurodevelopmental features, leading to a complex overlap between the conditions. Rett syndrome is a rare (orphan) genetic neurological disorder that occurs almost exclusively in females, affecting approximately 1 in 10,000. The condition leads to severe impairments, including speaking, walking, eating, and breathing. The hallmark of Rett syndrome is near constant repetitive hand movements and is classified as an autism spectrum disorder (ASD). The drug Trofinetide (Daybue) was approved to treat Rett syndrome in 2023 by Acadia Pharmaceuticals.
Rett綜合徵和自閉症在遺傳、臨床和神經發育特徵上有很多共同之處,導致兩種疾病有着複雜的重疊。Rett綜合徵是一種罕見(孤兒)的遺傳性神經疾病,幾乎只在女性中發生,大約有1/10,000的患病率。該疾病導致嚴重的障礙,包括說話、走路、吃飯和呼吸困難。Rett綜合徵的特點是近乎不斷的重複手部動作,被歸類爲自閉譜系障礙(ASD)。藥品Trofinetide (Daybue)在2023年由阿卡迪亞藥品公司獲批用於治療Rett綜合徵。
"Based on our success of MB204 in rapidly improving social behaviours in the Oprm1 mouse model of autism after a single oral dose, we are very interested in testing the chronic effect of MB204 in a head-to-head study against the approved drug Trofinetide in the Mecp2 mouse model," commented Dr. Le Merrer. "Based on our previous experience with MB204 and Istradefylline, we believe modulation of the adenosine A2a receptor, the target of both drugs, could improve outcomes in Mecp2 mice and ultimately patients with Rett syndrome as well as other forms of autism."
"基於我們在Oprm1自閉症小鼠模型中單次口服給予MB204迅速改善社交行爲的成功,我們非常有興趣測試MB204的慢性效應,並與獲批藥物Trofinetide在Mecp2小鼠模型中進行頭對頭的研究",Le Merrer博士評論道。"根據我們以前在MB204和Istradefylline上的經驗,我們認爲調節腺苷A2a受體,這兩種藥物的靶標,可以改善Mecp2小鼠和最終患有Rett綜合症以及其他形式的自閉症的患者的預後。"
"The extension of our collaboration with the iBraiN Institute is an exciting and significant step towards Marvel's mission to develop effective treatments for complex neurological disorders," explained Rod Matheson Chief Executive Officer. "Marvel is hopeful that our ongoing research will yield impactful insights and a potential therapeutic option for Rett syndrome."
"延長與iBraiN研究所的合作,對於Marvel致力於開發複雜神經疾病有效治療的使命是一個令人興奮和重要的步驟," Rod Matheson首席執行官解釋說。"Marvel很有希望我們的持續研究將產生有價值的見解和Rett綜合徵的潛在治療選項。"
About Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.
關於奇妙生物科技公司:
Marvel Biosciences公司及其全資子公司Marvel生物技術公司是加拿大卡爾加里一家臨床前階段的藥品開發生物技術公司,利用"藥品重新開發"方法進行藥物開發。歷史上,當一種新的藥物類別被開發出來時,它被優化爲特定的作用靶標,但通常只被批准用於特定的疾病。通常,會發現涉及相同作用靶標的新疾病,但原始批准的藥物可能由於專利剩餘存續期不足,不足以對新的疾病適用。Marvel爲新的疾病適應研究和開發原批准藥物的新合成化學衍生物。由公司開發的新潛在資產,我們將會尋求專利保護。該公司認爲這種商業模式與傳統生物技術公司相比,能夠更少風險、成本和時間地開發其資產。
Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.
Marvel Biotechnology Inc.目前已經開發出幾種新化學實體,使用已知的過期藥物的合成化學衍生物來抑制A2a腺苷受體,適用於神經系統疾病(抑鬱症和焦慮症、阿爾茨海默病、ADHD)、癌症和非酒精性脂肪肝等非神經系統疾病。Marvel還在探索其他未公開的目標,以擴大其資產流水線。
Contact Information
聯繫信息
Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Marvel Biosciences Corp.
J. Roderick(Rod) Matheson,首席執行官。
馬克·威廉姆斯博士,總裁和首席科學官
電話:403 770 2469
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
TSX Venture Exchange及其監管服務提供商(如TSXV的政策中所定義的那樣)不承擔對本新聞發佈的充分性或準確性的責任。
All information contained in this news release with respect to the Company and its subsidiary, (collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
本新聞發佈中所有有關公司及其子公司(統稱“各方”)的信息均由Marvel分別提供,供本新聞發佈納入,並且各自的董事和高管人員都僅就有關方面相互依賴獲得了信息。
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
本新聞發佈可能包含前瞻性聲明和其他陳述,而不是歷史事實。前瞻性聲明通常用諸如“將”、“可能”、“應該”、“預期”和類似表達方式來識別。本發佈中包含的所有陳述,除歷史事實陳述外,包括但不限於有關公司未來計劃和目標的陳述,都是有風險和不確定性的前瞻性聲明。不保證這類聲明會證明是準確的,實際結果和未來事件可能會與這類聲明所預期的有所不同。可能導致實際結果與公司預期不同的重要因素包括本新聞發佈所述各方的風險以及其他風險和不確定性,其許多情況超出公司的控制範圍。因此,公司不能保證上述事件將按照此處或全部披露的條款發生,也不能保證時間的履行。本新聞發佈中包含的前瞻性聲明明確受到此警告聲明的約束。本新聞發佈中包含的前瞻性聲明是截至本新聞發佈日期所述的,公司將根據加拿大證券法的規定明確更新或修訂包含在其中的任何前瞻性聲明。
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
讀者應注意,用於準備任何前瞻性信息的假設可能被證明是不正確的。由於衆所周知的和未知的風險、不確定性和其他因素,許多情況會導致預測結果與實際結果不同。因此,公司無法保證上述事件將按照此處或全部披露的條款發生,也無法保證時間的履行。讀者應謹慎,不要過度依賴任何前瞻性信息。儘管管理層在準備時認爲這些信息是合理的,但實際結果可能證明是不正確的。本新聞發佈中含有的前瞻性聲明受到此警示聲明的明確限制,本新聞發佈中含有的前瞻性聲明是截至本新聞發佈日期所述的,公司將根據加拿大證券法的規定明確更新或修訂包含在其中的任何前瞻性聲明。